

Annex 2 Response of the Competent Authorities of New Zealand to the recommendations of Report ref. DG(SANCO)/2012-6533-MR of an audit carried out from 10 to 20 September 2012 in order to evaluate the monitoring of residues and contaminants in live animals and animal products, including controls on veterinary medicinal products;

N°.	Recommendation	Action Proposed by the Competent Authority
1	<p>To include testing for Groups B2a and B3c in the NCRP for farmed salmon in line with the provisions of Annex II to Council Directive 96/23/EC. <i>namely</i> <i>Group B2a – anthelmintics</i> <i>Group B3c – chemical elements</i></p>	<ol style="list-style-type: none"> 1. The Animal Products (Contaminant Monitoring and Surveillance) Notice 2012 (Schedule 1) issued June 2012 and provided to the FVO as part of the pre-audit documentation, includes the testing of farmed salmon for Group B2a. 2. Chemical element testing (Lead, Cadmium and Mercury) will be included in the 2012/2013 programme. 3. The current sampling plan will be amended and 15 samples will be tested for Group B2a and 15 samples will be tested for Group B3c. 4. Information on the testing of the salmon feed will be sought by MPI. This information, together with the previously supplied information on the compliant results for testing of Lead, Cadmium and Mercury, in wild caught fish and the results for the testing from 2012/2013, will be used to review the need for ongoing inclusion of Group B3c ('highly desirable') in future years. This review will be completed by December 2013
2	<p>To include testing for the anabolic steroid Methandriol in equine urine in line with the provisions of Article 11(1)(c) of Council Directive 96/23/EC.</p>	<ol style="list-style-type: none"> 1. Methandriol is registered in two products in New Zealand, and in both these, nandrolone is also present. MPI has used nandrolone as the marker for use of these products in equine animals. No detections have ever been reported in equine animals presented for slaughter. 2. In the event that Methandriol was registered with Nandrolone being absent, MPI will work with the primary testing laboratory and develop an appropriate equine urine method for Methandriol. 3. Irrespective the Competent Authority will commence development of a validated method for Methandriol in the 2014 calendar year.
3	<p>To review the list of analytes (particularly antibiotics) in the NCCP and</p>	<p>The NCCP draft Annual Plan for 2012/13 is currently being amended to</p>

N°.	Recommendation	Action Proposed by the Competent Authority
	<p>ensure that only those for which it can be verified that the screening method is fit for purpose, are included in the NCCP, as per the requirements of the fifth indent of Article 7 of Council Directive 96/23/EC <i>namely</i> <i>A list of the substances to be detected, methods of analysis, standards for interpreting the findings and in the case of substances listed in Annex 1, the number of samples to be taken, giving reasons for this number</i></p>	<p>address this recommendation and will be provided to the FVO. Only methods that meet the approach set out in response to recommendation 4 below will be used.</p>
4	<p>To ensure that all analytical methods used for either the NCRP or NCCP are validated to a standard equivalent to that required by Commission Decision 2002/657/EC.</p>	<p>All NCRP & NCCP methods are validated to CD 2002/675/EC or to an equivalent standard.</p> <ol style="list-style-type: none"> 1. Where a method is employed within the laboratory that is supplied as a validated commercial method (in accordance with CD 2002/675/EC or to an equivalent standard e.g. IUPAC6) , it will be used in accordance with the Single Laboratory Validation as described in CAC/GL 71-2009 'Single Laboratory Validation – The Criteria Approach'. Validated methods that are employed within the laboratory for the testing of official samples must meet suitability and fitness for purpose criteria. The only exception to this approach is where an emergency situation arises e.g. the melamine situation. 2. MPI is working with laboratory (Laboratory B) to review options to address deficiencies identified during the course of the audit, including the formalizing of an internal SOP for validation by 30 November 2012 and reviewing relevant method validations based on this SOP. 3. Alternative testing at Laboratory A is being used for the analysis of inhibitory substances until validation of the inhibitory substances method at Laboratory B is complete. The alternative method was reviewed by the FVO during the course of the mission and is validated for the compounds included in the NCCP draft Annual Plan for 2012/13

Action Plan received from CA on 16 November 2012